

PRIMARY IMMUNODEFICIENCIES GENE PANEL DG 2.11 (322 genes)

| <i>Gene</i> | <i>Median</i> | <i>% covered > 10x</i> | <i>% covered > 20x</i> | <i>Associated Phenotype description and OMIM disease ID</i> |
|-------------|---------------|-------------------------------|-------------------------------|---|
| ACD | 135.2 | 100 | 98 | ?Dyskeratosis congenita, autosomal recessive 7, 616553 ?Dyskeratosis congenita, autosomal dominant 6, 616553 |
| ACP5 | 196.7 | 100 | 99 | Spondyloenchondrodysplasia with immune dysregulation, 607944 |
| ACTB | 129.3 | 99 | 94 | Baraitser-Winter syndrome 1, 243310 ?Dystonia, juvenile-onset, 607371 |
| ADA | 113.2 | 98 | 97 | Adenosine deaminase deficiency, partial, 102700 Severe combined immunodeficiency due to ADA deficiency, 102700 |
| ADAM17 | 139.6 | 97 | 93 | ?Inflammatory skin and bowel disease, neonatal, 1, 614328 |
| ADAR | 122.6 | 100 | 99 | Aicardi-Goutieres syndrome 6, 615010 Dyschromatosis symmetrica hereditaria, 127400 |
| AGA | 130.2 | 100 | 100 | Aspartylglucosaminuria, 208400 |
| AICDA | 139.3 | 89 | 82 | Immunodeficiency with hyper-IgM, type 2, 605258 |
| AIRE | 72.7 | 99 | 93 | Autoimmune polyendocrinopathy syndrome , type I, with or without reversible metaphyseal dysplasia, 240300 |
| AK2 | 110.3 | 99 | 96 | Reticular dysgenesis, 267500 |
| ALG13 | 87.4 | 98 | 94 | Epileptic encephalopathy, early infantile, 36, 300884 |
| AP3B1 | 95 | 97 | 90 | Hermansky-Pudlak syndrome 2, 608233 |
| APOL1 | 188 | 100 | 100 | {End-stage renal disease, nondiabetic, susceptibility to}, 612551 {Glomerulosclerosis, focal segmental, 4, susceptibility to}, 612551 |
| ATM | 109.8 | 99 | 94 | Ataxia-telangiectasia, 208900 Lymphoma, B-cell non-Hodgkin, somatic Lymphoma, mantle cell, somatic T-cell prolymphocytic leukemia, somatic {Breast cancer, susceptibility to}, 114480 |
| BLM | 116.3 | 99 | 96 | Bloom syndrome, 210900 |
| BLNK | 94.2 | 94 | 91 | Agammaglobulinemia 4, 613502 |
| BLOC1S6 | 97.3 | 98 | 91 | Hermansky-pudlak syndrome 9, 614171 |
| BTK | 115.5 | 100 | 99 | Agammaglobulinemia and isolated hormone deficiency, 307200 Agammaglobulinemia, X-linked 1, 300755 |

| | | | | |
|--------|-------|-----|-----|---|
| C1QA | 120.3 | 100 | 99 | C1q deficiency, 613652 |
| C1QB | 183.5 | 100 | 99 | C1q deficiency, 613652 |
| C1QC | 198.3 | 100 | 99 | C1q deficiency, 613652 |
| C1R | 157.2 | 100 | 100 | C1r/C1s deficiency, combined, 216950 |
| C1S | 121.1 | 100 | 99 | C1s deficiency, 613783 |
| C2 | 20 | 15 | 15 | C2 deficiency, 217000 {Macular degeneration, age-related, 14, reduced risk of}, 615489 |
| C3 | 145.8 | 100 | 99 | C3 deficiency, 613779 {Hemolytic uremic syndrome, atypical, susceptibility to, 5}, 612925 {Macular degeneration, age-related, 9}, 611378 |
| C4A | 22.8 | 24 | 24 | C4a deficiency, 614380 [Blood group, Rodgers], 614374 |
| C4B | 22.5 | 24 | 24 | C4B deficiency, 614379 |
| C5 | 134.4 | 98 | 95 | C5 deficiency, 609536 [Eculizumab, poor response to], 615749 |
| C6 | 157.5 | 100 | 99 | C6 deficiency, 612446 Combined C6/C7 deficiency |
| C7 | 132.2 | 99 | 94 | C7 deficiency, 610102 |
| C8A | 120.1 | 100 | 99 | C8 deficiency, type I, 613790 |
| C8B | 135.9 | 99 | 99 | C8 deficiency, type II, 613789 |
| C9 | 133.5 | 100 | 98 | C9 deficiency, 613825 {Macular degeneration, age-related, 15, susceptibility to}, 615591 |
| CARD11 | 154.9 | 99 | 98 | B-cell expansion with NFKB and T-cell anergy, 616452 Immunodeficiency 11, 615206 |
| CARD14 | 116.5 | 99 | 97 | Pityriasis rubra pilaris, 173200 Psoriasis 2, 602723 |
| CARD9 | 120.6 | 98 | 96 | Candidiasis, familial, 2, autosomal recessive, 212050 |
| CASP10 | 117.6 | 99 | 98 | Autoimmune lymphoproliferative syndrome, type II, 603909 Gastric cancer, somatic, 613659 Lymphoma, non-Hodgkin, somatic, 605027 |
| CASP8 | 151.4 | 100 | 99 | Hepatocellular carcinoma, somatic, 114550 ?Autoimmune lymphoproliferative syndrome, type IIB, 607271 {Breast cancer, protection against}, 114480 {Lung cancer, protection against}, 211980 |

| | | | | |
|--------|-------|-----|-----|--|
| CD19 | 88.8 | 99 | 98 | Immunodeficiency, common variable, 3, 613493 |
| CD247 | 101.5 | 100 | 98 | ?Immunodeficiency 25, 610163 |
| CD27 | 118.4 | 100 | 99 | Lymphoproliferative syndrome 2, 615122 |
| CD3D | 194 | 100 | 100 | Immunodeficiency 19, 615617 |
| CD3E | 152.3 | 100 | 99 | Immunodeficiency 18, 615615 Immunodeficiency 18, SCID variant, 615615 |
| CD3G | 157.1 | 100 | 100 | Immunodeficiency 17, CD3 gamma deficient, 615607 |
| CD40 | 172.6 | 100 | 99 | Immunodeficiency with hyper-IgM, type 3, 606843 |
| CD40LG | 127.5 | 96 | 87 | Immunodeficiency, X-linked, with hyper-IgM, 308230 |
| CD46 | 115.2 | 97 | 93 | {Hemolytic uremic syndrome, atypical, susceptibility to, 2}, 612922 |
| CD55 | 144.1 | 93 | 86 | [Blood group Cromer], 613793 |
| CD59 | 200.8 | 93 | 86 | Hemolytic anemia, CD59-mediated, with or without immune-mediated polyneuropathy, 612300 |
| CD79A | 128.5 | 99 | 97 | Agammaglobulinemia 3, 613501 |
| CD79B | 211 | 100 | 100 | Agammaglobulinemia 6, 612692 |
| CD81 | 143 | 99 | 98 | Immunodeficiency, common variable, 6, 613496 |
| CD8A | 105.8 | 99 | 99 | CD8 deficiency, familial, 608957 |
| CDCA7 | 109.2 | 100 | 99 | Immunodeficiency-centromeric instability-facial anomalies syndrome 3, 616910 |
| CDKN2B | 86.3 | 100 | 99 | No OMIM phenotype Renal cell carcinoma (Jafri (2015) Cancer Discov 5, 723) Multiple endocrine neoplasia 1 (Agarwal (2009) J Clin Endocrinol Metab 94, 1826) ?Melanoma (Foley (2015) EBioMedicine 2,74) ?Parathyroid adenoma (Costa-Guda (2013) Horm Cancer 4, 301) |
| CEBPE | 71.2 | 99 | 95 | Specific granule deficiency, 245480 |
| CECR1 | 101.5 | 99 | 99 | Polyarteritis nodosa, childhood-onset, 615688 ?Sneddon syndrome, 182410 |
| CFB | 33.4 | 23 | 23 | ?Complement factor B deficiency, 615561 {Hemolytic uremic syndrome, atypical, susceptibility to, 4}, 612924 {Macular degeneration, age-related, 14, reduced risk of}, 615489 |
| CFD | 80.9 | 89 | 81 | Complement factor D deficiency, 613912 |
| CFH | 183.1 | 98 | 95 | Basal laminar drusen, 126700 Complement factor H deficiency, 609814 {Hemolytic uremic syndrome, atypical, susceptibility to, 1}, 235400 {Macular degeneration, age-related, 4}, 610698 |
| CFHR1 | 234.8 | 95 | 94 | {Hemolytic uremic syndrome, atypical, susceptibility to}, 235400 |

| | | | | |
|---------|-------|-----|-----|---|
| | | | | {Macular degeneration, age-related, reduced risk of}, 603075 |
| CFHR3 | 103 | 92 | 87 | {Hemolytic uremic syndrome, atypical, susceptibility to}, 235400 {Macular degeneration, age-related, reduced risk of}, 603075 |
| CFHR5 | 99.6 | 98 | 93 | Nephropathy due to CFHR5 deficiency, 614809 |
| CFI | 152.5 | 98 | 96 | Complement factor I deficiency, 610984 {Hemolytic uremic syndrome, atypical, susceptibility to, 3}, 612923 {Macular degeneration, age-related, 13, susceptibility to}, 615439 |
| CFP | 96.5 | 98 | 93 | Properdin deficiency,X-linked, 312060 |
| CFTR | 124 | 99 | 96 | Congenital bilateral absence of vas deferens, 277180 Cystic fibrosis, 219700 Sweat chloride elevation without CF {Bronchiectasis with or without elevated sweat chloride 1, modifier of}, 211400 {Hypertrypsinemia, neonatal} {Pancreatitis, idiopathic}, 167800 |
| CHD7 | 150.9 | 99 | 98 | CHARGE syndrome, 214800 Hypogonadotropic hypogonadism 5 with or without anosmia, 612370 |
| CIITA | 125.3 | 100 | 100 | Bare lymphocyte syndrome, type II, complementation group A, 209920 {Rheumatoid arthritis, susceptibility to}, 180300 |
| CLEC4D | 140.1 | 100 | 100 | No OMIM phenotype |
| CLEC7A | 150.6 | 100 | 99 | Candidiasis, familial, 4, autosomal recessive, 613108 {Aspergillosis, susceptibility to}, 614079 |
| COLEC11 | 203.1 | 100 | 100 | 3MC syndrome 2, 265050 |
| COPA | 133.2 | 100 | 100 | {Autoimmune interstitial lung, joint, and kidney disease}, 616414 |
| CORO1A | 154.7 | 99 | 96 | Immunodeficiency 8, 615401 |
| CR2 | 160.7 | 100 | 99 | Immunodeficiency, common variable, 7, 614699 {Systemic lupus erythematosus, susceptibility to, 9}, 610927 |
| CREBBP | 123.5 | 99 | 96 | Rubinstein-Taybi syndrome, 180849 |
| CSF2RA | 66.2 | 89 | 88 | Surfactant metabolism dysfunction, pulmonary, 4, 300770 |
| CSF3R | 94.5 | 99 | 96 | ?Neutrophilia, hereditary, 162830 |
| CTC1 | 119 | 100 | 99 | Cerebroretinal microangiopathy with calcifications and cysts, 612199 |

| | | | | |
|---------|-------|-----|-----|---|
| CTLA4 | 194.1 | 100 | 100 | Autoimmune lymphoproliferative syndrome, type V, 616100 {Celiac disease, susceptibility to, 3}, 609755 {Diabetes mellitus, insulin-dependent, 12}, 601388 {Hashimoto thyroiditis}, 140300 {Systemic lupus erythematosus, susceptibility to}, 152700 |
| CTSC | 127.4 | 100 | 100 | Haim-Munk syndrome, 245010 Papillon-Lefevre syndrome, 245000 Periodontitis 1, juvenile, 170650 |
| CXCR4 | 202.8 | 100 | 99 | Myelokathexis, isolated WHIM syndrome, 193670 |
| CYBA | 97.4 | 78 | 71 | Chronic granulomatous disease, autosomal, due to deficiency of CYBA, 233690 |
| CYBB | 111.5 | 99 | 99 | Chronic granulomatous disease, X-linked, 306400 Immunodeficiency 34, mycobacteriosis, X-linked, 300645 |
| DCLRE1C | 128.9 | 98 | 94 | Omenn syndrome, 603554 Severe combined immunodeficiency, Athabascan type, 602450 |
| DDX58 | 122.8 | 98 | 95 | Singleton-Merten syndrome 2, 616298 |
| DHFR | 48.5 | 91 | 71 | Megaloblastic anemia due to dihydrofolate reductase deficiency, 613839 |
| DKC1 | 112.6 | 99 | 98 | Dyskeratosis congenita, X-linked, 305000 |
| DNASE1 | 201.3 | 100 | 100 | {Systemic lupus erythematosus, susceptibility to}, 152700 |
| DNMT3B | 125 | 100 | 100 | Immunodeficiency-centromeric instability-facial anomalies syndrome 1, 242860 |
| DOCK2 | 143.9 | 100 | 99 | Immunodeficiency 40, 616433 |
| DOCK8 | 129.2 | 100 | 99 | Hyper-IgE recurrent infection syndrome, autosomal recessive, 243700 |
| ELANE | 80.9 | 99 | 95 | Neutropenia, cyclic, 162800 Neutropenia, severe congenital 1, autosomal dominant, 202700 |
| ELF4 | 77.3 | 99 | 97 | No OMIM phenotype ?Immunodeficiency, primary, modifier of (Stray-Pedersen (2017) J Allergy Clin Immunol 139,232) ?Hypogammaglobulinaemia (Stewart (2005) Curr Opin Allergy Clin Immunol 5,510) |
| EPG5 | 126.1 | 99 | 97 | Vici syndrome, 242840 |
| ERCC2 | 123.8 | 100 | 99 | Cerebrooculofacioskeletal syndrome 2, 610756 Trichothiodystrophy 1, photosensitive, 601675 Xeroderma pigmentosum, group D, 278730 |
| ERCC3 | 113.3 | 99 | 98 | Trichothiodystrophy 2, photosensitive, 616390 Xeroderma pigmentosum, group B, 610651 |
| F12 | 111.6 | 100 | 99 | Angioedema, hereditary, type III, 610618 |

| | | | | |
|---------|-------|-----|-----|--|
| | | | | Factor XII deficiency, 234000 |
| FADD | 142.9 | 100 | 99 | Infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovasuclar malformations, 613759 |
| FAM105B | 149.7 | 90 | 86 | Autoinflammation,pannulitis, and dermatosis syndrome, 617099 |
| FAS | 271.9 | 100 | 99 | Autoimmune lymphoproliferative syndrome, type IA, 601859 Squamous cell carcinoma, burn scar-related, somatic {Autoimmune lymphoproliferative syndrome}, 601859 |
| FASLG | 86.1 | 100 | 98 | Autoimmune lymphoproliferative syndrome, type IB, 601859 {Lung cancer, susceptibility to}, 211980 |
| FCGR1A | 82.5 | 47 | 46 | [IgG receptor I, phagocytic, familial deficiency of] |
| FCGR2A | 245.1 | 100 | 100 | {Lupus nephritis, susceptibility to}, 152700 {Malaria, severe, susceptibility to}, 611162 {Pseudomonas aeruginosa, susceptibility to chronic infection by, in cystic fibrosis}, 219700 |
| FCGR2B | 166.1 | 99 | 97 | {Malaria, resistance to}, 611162 {Systemic lupus erythematosus, susceptibility to}, 152700 |
| FCGR3A | 244.9 | 100 | 99 | Immunodeficiency 20, 615707 |
| FCGR3B | 176.7 | 99 | 98 | Neutropenia, alloimmune neonatal |
| FCN3 | 127.8 | 100 | 99 | Immunodeficiency due to ficolin 3 deficiency, 613860 |
| FERMT3 | 122.6 | 100 | 98 | Leukocyte adhesion deficiency,type III,612840 |
| FOXN1 | 112.9 | 100 | 99 | T-cell immunodeficiency, congenital alopecia, and nail dystrophy, 601705 |
| FOXP3 | 125.7 | 98 | 91 | Immunodysregulation, polyendocrinopathy, and enteropathy, X-linked, 304790 {Diabetes mellitus, type I, susceptibility to}, 222100 |
| FPR1 | 217.3 | 100 | 100 | No OMIM phenotype {Periodontitis, aggressive, association with} (Gunji (2007) Biochem Biophys Res Commun 364,7) {Earlier onset of Alzheimer disease, association with} (Velez (2016) Am J Med Genet B Neuropsychiatr Genet 171,1116) |
| G6PC | 180.8 | 100 | 100 | Glycogen storage disease Ia, 232200 |
| G6PC3 | 124 | 100 | 100 | Dursun syndrome, 612541 Neutropenia, severe congenital 4, autosomal recessive, 612541 |
| G6PD | 119.4 | 99 | 97 | Favism, 134700 Hemolytic anemia due to G6PD deficiency, 300908 {Resistance to malaria due to G6PD deficiency}, 611162 |

| | | | | |
|--------|-------|-----|-----|---|
| GATA2 | 119.6 | 99 | 98 | Emberger syndrome, 614038 Immunodeficiency 21, 614172 {Leukemia, acute myeloid, susceptibility to}, 601626 {Myelodysplastic syndrome, susceptibility to}, 614286 |
| GFI1 | 83.1 | 99 | 92 | Neutropenia, nonimmune chronic idiopathic, of adults, 607847 Neutropenia, severe congenital 2, autosomal dominant, 613107 |
| GJC2 | 42.1 | 68 | 58 | Leukodystrophy, hypomyelinating, 2, 608804 Lymphedema, hereditary, IC, 613480 Spastic paraparesis 44, autosomal recessive, 613206 |
| GRHL2 | 134.6 | 100 | 100 | Deafness, autosomal dominant 28, 608641 Ectodermal dysplasia/short stature syndrome, 616029 |
| GTF2H5 | 113.7 | 100 | 99 | Trichothiodystrophy 3, photosensitive, 616395 |
| HAX1 | 136.6 | 100 | 100 | Neutropenia, severe congenital 3, autosomal recessive, 610738 |
| HELLS | 93.4 | 94 | 86 | Immunodeficiency-centromeric instability-facial anomalies syndrome 4, 616911 |
| ICOS | 159.9 | 100 | 100 | Immunodeficiency, common variable, 1, 607594 |
| IFIH1 | 113.4 | 99 | 97 | Aicardi-Goutieres syndrome 7, 615846 Singleton-Merten syndrome 1, 182250 |
| IFNGR1 | 133 | 99 | 97 | Immunodeficiency 27A, mycobacteriosis, AR, 209950 Immunodeficiency 27B, mycobacteriosis, AD, 615978 {H. pylori infection, susceptibility to}, 600263 {Hepatitis B virus infection, susceptibility to}, 610424 {Tuberculosis infection, protection against}, 607948 {Tuberculosis, susceptibility to}, 607948 |
| IFNGR2 | 142.2 | 93 | 93 | Immunodeficiency 28, mycobacteriosis, 614889 |
| IGHM | 196.1 | 100 | 100 | Agammaglobulinemia 1, 601495 |
| IGLL1 | 86.2 | 99 | 94 | Agammaglobulinemia 2, 613500 |
| IKBKB | 123.7 | 98 | 94 | Immunodeficiency 15, 615592 |
| IKBKG | 52.9 | 84 | 73 | Ectodermal dysplasia, hypohidrotic, with immune deficiency, 300291 Ectodermal, dysplasia, anhidrotic, lymphedema and immunodeficiency, 300301 Immunodeficiency 33, 300636 Immunodeficiency, isolated, 300584 Incontinentia pigmenti, 308300 Invasive pneumococcal disease, recurrent isolated, 2, 300640 |
| IKZF1 | 183.4 | 100 | 100 | Immunodeficiency, common variable, 1, 616873 |

| | | | | |
|---------|-------|-----|-----|--|
| IL10RA | 142.3 | 100 | 99 | Inflammatory bowel disease 28, early onset, autosomal recessive, 613148 |
| IL10RB | 168.7 | 98 | 96 | Inflammatory bowel disease 25, early onset, autosomal recessive, 612567 {Hepatitis B virus, susceptibility to}, 610424 |
| IL12B | 121.4 | 100 | 99 | Immunodeficiency 29, mycobacteriosis, 614890 |
| IL12RB1 | 124.5 | 97 | 94 | Immunodeficiency 30, 614891 |
| IL17F | 86 | 99 | 94 | ?Candidiasis, familial, 6, autosomal dominant, 613956 |
| IL17RA | 140.7 | 99 | 96 | Immunodeficiency 51, 613953 |
| IL1RN | 162.9 | 100 | 100 | Interleukin 1 receptor antagonist deficiency, 612852 {Gastric cancer risk after H. pylori infection}, 137215 {Microvascular complications of diabetes 4}, 612628 |
| IL2 | 65.1 | 93 | 77 | Severe combined immunodeficiency due to IL2 deficiency |
| IL21R | 128.7 | 100 | 100 | Immunodeficiency, primary, autosomal recessive, IL21R-related, 615207 [IgE, elevated level of], 147050 |
| IL2RA | 116.7 | 100 | 99 | Immunodeficiency 41 with lymphoproliferation and autoimmunity, 606367 {Diabetes, mellitus, insulin-dependent, susceptibility to, 10}, 601942 |
| IL2RG | 65.7 | 99 | 97 | Combined immunodeficiency, X-linked, moderate, 312863 Severe combined immunodeficiency, X-linked, 300400 |
| IL36RN | 99.1 | 100 | 100 | Psoriasis 14, pustular, 614204 |
| IL7R | 129.2 | 99 | 99 | Severe combined immunodeficiency, T-cell negative, B-cell/natural killer cell-positive type, 608971 |
| INSR | 141.1 | 97 | 94 | Diabetes mellitus, insulin-resistant, with acanthosis nigricans, 610549 Hyperinsulinemic hypoglycemia, familial, 5, 609968 Leprechaunism, 246200 Rabson-Mendenhall syndrome, 262190 |
| IRAK4 | 95.4 | 98 | 90 | Invasive pneumococcal disease, recurrent isolated, 1, 610799 IRAK4 deficiency, 607676 |
| IRF7 | 90 | 99 | 99 | ?Immunodeficiency 39, 616345 |
| IRF8 | 114.6 | 99 | 97 | Immunodeficiency 32A, mycobacteriosis, autosomal dominant, 614893 Immunodeficiency 32B, monocyte and dendritic cell deficiency, autosomal recessive, 614894 |
| ISG15 | 160.6 | 100 | 100 | Immunodeficiency 38, 616126 |
| ITCH | 124.7 | 95 | 94 | Autoimmune disease, multisystem, with facial dysmorphism, 613385 |
| ITGB2 | 152.5 | 100 | 99 | Leukocyte adhesion deficiency, 116920 |
| ITK | 125.3 | 100 | 99 | Lymphoproliferative syndrome 1, 613011 |
| JAGN1 | 147.3 | 100 | 100 | Neutropenia, severe congenital, 6, autosomal recessive, 616022 |

| | | | | |
|---------|-------|-----|----|---|
| JAK2 | 90.5 | 95 | 94 | Erythrocytosis, somatic, 133100 Leukemia, acute myeloid, somatic, 601626 Myelofibrosis, somatic, 254450 Polycythemia vera, somatic, 263300 Thrombocythemia 3, 614521 {Budd-Chiari syndrome, somatic}, 600800 |
| JAK3 | 104.3 | 98 | 95 | SCID, autosomal recessive, T-negative/B-positive type, 600802 |
| KMT2D | 142.2 | 99 | 99 | Kabuki syndrome 1, 147920 |
| KRAS | 64.6 | 99 | 98 | Bladder cancer, somatic, 109800 Breast cancer, somatic, 114480 Cardiofaciocutaneous syndrome 2, 615278 Gastric cancer, somatic, 137215 Leukemia, acute myeloid, 601626 Lung cancer, somatic, 211980 Noonan syndrome 3, 609942 Pancreatic carcinoma, somatic, 260350 RAS-associated autoimmune leukoproliferative disorder, 614470 Schimmelpenning-Feuerstein-Mims syndrome, somatic mosaic, 163200 |
| LAMTOR2 | 167.3 | 100 | 99 | Immunodeficiency due to defect in MAPBP-interacting protein, 610798 |
| LCK | 161.8 | 98 | 95 | ?Immunodeficiency 22, 615758 |
| LIG1 | 95.4 | 100 | 99 | DNA ligase I deficiency |
| LIG4 | 165.3 | 100 | 99 | LIG4 syndrome, 606593 {Multiple myeloma, resistance to}, 254500 |
| LPIN2 | 111.6 | 100 | 99 | Majeed syndrome, 609628 |
| LRBA | 134.3 | 99 | 97 | Immunodeficiency, common variable, 8, with autoimmunity, 614700 |
| LRRC8A | 273.8 | 100 | 99 | Agammaglobulinemia 5, 613506 |
| LTBP3 | 113.8 | 98 | 94 | Dental anomalies and short stature, 601216 |
| LYST | 134.6 | 97 | 93 | Chediak-Higashi syndrome, 214500 |
| MAGT1 | 102.7 | 98 | 95 | Immunodeficiency, X-linked, with magnesium defect, Epstein-Barr virus infection and neoplasia, 300853 |
| MAL | 138.9 | 100 | 99 | No OMIM phenotype |
| MALT1 | 136.6 | 89 | 85 | Immunodeficiency 12, 615468 |
| MAN2B1 | 122.5 | 99 | 96 | Mannosidosis, alpha-, types I and II, 248500 |
| MANBA | 119.9 | 99 | 97 | Mannosidosis, beta, 248510 |
| MASP2 | 139.8 | 100 | 99 | MASP2 deficiency, 613791 |

| | | | | |
|--------|-------|-----|-----|---|
| MBL2 | 109.8 | 100 | 99 | {Chronic infections, due to MBL deficiency}, 614372 |
| MC2R | 213 | 100 | 100 | Glucocorticoid deficiency, due to ACTH unresponsiveness, 202200 |
| MCM4 | 164.5 | 99 | 98 | Natural killer cell and glucocorticoid deficiency with DNA repair defect, 609981 |
| MEFV | 108.8 | 94 | 91 | Familial Mediterranean fever, AD, 134610 Familial Mediterranean fever, AR, 249100 |
| MKL1 | 102.2 | 97 | 92 | Megakaryoblastic leukemia, acute |
| MPO | 151.1 | 100 | 99 | Myeloperoxidase deficiency, 254600 {Alzheimer disease, susceptibility to}, 104300 {Lung cancer, protection against, in smokers} |
| MRE11A | 51.2 | 95 | 82 | Ataxia-telangiectasia-like disorder, 604391 |
| MS4A1 | 123.6 | 99 | 96 | Immunodeficiency, common variable, 5, 613495 |
| MTHFD1 | 139.6 | 99 | 98 | {Abruptio placentae, susceptibility to} {Spina bifida, folate-sensitive, susceptibility to}, 601634 |
| MVK | 136.7 | 100 | 99 | Hyper-IgD syndrome, 260920 Mevalonic aciduria, 610377 Porokeratosis 3, multiple types, 175900 |
| MYD88 | 186.8 | 100 | 99 | Macroglobulinemia, Waldenstrom, somatic, 153600 Pyogenic bacterial infections, recurrent, due to MYD88 deficiency, 612260 |
| NBN | 80.5 | 99 | 94 | Aplastic anemia, 609135 Leukemia, acute lymphoblastic, 613065 Nijmegen breakage syndrome, 251260 |
| NCF1 | 23.8 | 25 | 22 | Chronic granulomatous disease due to deficiency of NCF-1, 233700 |
| NCF2 | 124.3 | 100 | 99 | Chronic granulomatous disease due to deficiency of NCF-2, 233710 |
| NCF4 | 158.9 | 100 | 100 | ?Granulomatous disease, chronic, autosomal recessive, cytochrome b-positive, type III, 613960 |
| NCSTN | 112.1 | 100 | 99 | Acne inversa, familial, 1, 142690 |
| NDNL2 | 130 | 99 | 98 | Lung disease, immunodeficiency, and chromosome breakage syndrome, 617241 |
| NFKB1 | 105.4 | 99 | 96 | Immunodeficiency, common variable, 12, 616576 |
| NFKB2 | 123.4 | 97 | 92 | Immunodeficiency, common variable, 10, 615577 |
| NFKBIA | 116.5 | 98 | 93 | Ectodermal dysplasia, anhidrotic, with T-cell immunodeficiency, 612132 |
| NHEJ1 | 80.4 | 100 | 99 | Severe combined immunodeficiency with microcephaly, growth retardation, and sensitivity to ionizing radiation, 611291 |
| NHP2 | 111.1 | 100 | 100 | Dyskeratosis congenita, autosomal recessive 2, 613987 |

| | | | | |
|--------|-------|-----|-----|---|
| NKX2-5 | 83.2 | 100 | 99 | Atrial septal defect 7, with or without AV conduction defects, 108900 Conotruncal heart malformations, variable, 217095 Hypoplastic left heart syndrome 2, 614435 Hypothyroidism, congenital nongoitrous, 5, 225250 Tetralogy of Fallot, 187500 Ventricular septal defect 3, 614432 |
| NLRC4 | 180 | 100 | 99 | Autoinflammation with infantile enterocolitis, 616050 ?Familial cold autoinflammatory syndrome 4, 616115 |
| NLRP1 | 126.4 | 99 | 96 | ?Corneal intraepithelial dyskeratosis and ectodermal dysplasia, 615225 {Vitiligo-associated multiple autoimmune disease susceptibility 1}, 606579 |
| NLRP12 | 165.4 | 99 | 99 | Familial cold autoinflammatory syndrome 2, 611762 |
| NLRP3 | 150.5 | 100 | 100 | CINCA syndrome, 607115 Familial cold-induced inflammatory syndrome 1, 120100 Muckle-Wells syndrome, 191900 |
| NOD2 | 136 | 100 | 99 | Blau syndrome, 186580 Yao syndrome, 617321 {Inflammatory bowel disease 1}, 266600 {Psoriatic arthritis, susceptibility to}, 607507 |
| NOP10 | 160.6 | 100 | 100 | Dyskeratosis congenita, autosomal recessive 1, 224230 |
| NRAS | 188.2 | 100 | 100 | Colorectal cancer, somatic, 114500 Epidermal nevus, somatic, 162900 Melanocytic nevus syndrome, congenital, somatic, 137550 Neurocutaneous melanosis, somatic, 249400 Noonan syndrome 6, 613224 Schimmelpenning-Feuerstein-Mims syndrome, somatic mosaic, 163200 Thyroid carcinoma, follicular, somatic, 188470 ?RAS-associated autoimmune lymphoproliferative syndrome type IV, somatic, 614470 |
| ORAI1 | 226.8 | 92 | 89 | Immunodeficiency 9, 612782 Myopathy, tubular aggregate, 2, 615883 |
| PARN | 128.3 | 99 | 98 | Dyskeratosis congenita, autosomal recessive 6, 616353 Pulmonary fibrosis and/or bone marrow failure, telomere-related, 4, 616371 |
| PAX5 | 118.9 | 98 | 95 | {Leukemia, acute lymphoblastic, susceptibility to, 3}, 615545 |
| PBX1 | 113.2 | 99 | 95 | Leukemia, acute pre-B-cell, 176310 |
| PCCA | 103.1 | 96 | 89 | Propionicacidemia, 606054 |
| PCCB | 129.9 | 98 | 96 | Propionicacidemia, 606054 |

| | | | | |
|---------|-------|-----|-----|---|
| PEPD | 116.3 | 99 | 98 | Prolidase deficiency, 170100 |
| PGM3 | 191.6 | 99 | 99 | Immunodeficiency 23, 615816 |
| PIGA | 90.8 | 90 | 81 | Multiple congenital anomalies-hypotonia-seizures syndrome 2, 300868 Paroxysmal nocturnal hemoglobinuria, somatic, 300818 |
| PIK3CD | 132.6 | 99 | 96 | Immunodeficiency 14, 615513 |
| PIK3R1 | 129.3 | 99 | 97 | Immunodeficiency 36, 616005 SHORT syndrome, 269880 ?Agammaglobulinemia 7, autosomal recessive, 615214 |
| PLCG2 | 118.9 | 100 | 99 | Autoinflammation, antibody deficiency, and immune dysregulation syndrome, 614878 Familial cold autoinflammatory syndrome 3, 614468 |
| PLG | 115.4 | 87 | 86 | Dysplasminogenemia, 217090 Plasminogen deficiency, type I, 217090 |
| PMM2 | 141.3 | 99 | 99 | Congenital disorder of glycosylation, type Ia, 212065 |
| PNP | 151.2 | 100 | 99 | Immunodeficiency due to purine nucleoside phosphorylase deficiency, 613179 |
| POT1 | 90.6 | 99 | 95 | {Glioma susceptibility 9}, 616568 {Melanoma, cutaneous malignant, susceptibility to, 10}, 615848 |
| PRF1 | 134.2 | 100 | 99 | Aplastic anemia, 609135 Hemophagocytic lymphohistiocytosis, familial, 2, 603553 Lymphoma, non-Hodgkin, 605027 |
| PRKCD | 181.6 | 100 | 99 | Autoimmune lymphoproliferative syndrome, type III, 615559 |
| PRKDC | 106.7 | 98 | 94 | Immunodeficiency 26, with or without neurologic abnormalities, 615966 |
| PRPS1 | 150.5 | 100 | 100 | Arts syndrome, 301835 Charcot-Marie-Tooth disease, X-linked recessive, 5, 311070 Deafness, X-linked 1, 304500 Gout, PRPS-related, 300661 Phosphoribosylpyrophosphate synthetase superactivity, 300661 |
| PSENEN | 67.4 | 100 | 98 | Acne inversa, familial, 2, 613736 |
| PSMB8 | 14.8 | 12 | 12 | Autoinflammation, lipodystrophy, and dermatosis syndrome, 256040 |
| PSTPIP1 | 88.5 | 99 | 97 | Pyogenic sterile arthritis, pyoderma gangrenosum, and acne, 604416 |
| PTPN11 | 103.4 | 97 | 92 | LEOPARD syndrome 1, 151100 Leukemia, juvenile myelomonocytic, somatic, 607785 Metachondromatosis, 156250 Noonan syndrome 1, 163950 |

| | | | | |
|----------|-------|-----|-----|--|
| PTPN22 | 134.4 | 98 | 91 | {Diabetes, type 1, susceptibility to}, 222100 {Rheumatoid arthritis, susceptibility to}, 180300 {Systemic lupus erythematosus susceptibility to}, 152700 |
| PTPRC | 101.6 | 93 | 86 | Severe combined immunodeficiency, T cell-negative, B-cell/natural killer-cell positive, 608971 {Hepatitis C virus, susceptibility to}, 609532 |
| PTRF | 137.5 | 99 | 99 | Lipodystrophy, congenital generalized, type 4, 613327 |
| RAB27A | 144.1 | 100 | 99 | Griselli syndrome, type 2, 607624 |
| RAC2 | 104.2 | 100 | 99 | Neutrophil immunodeficiency syndrome, 608203 |
| RAG1 | 206.9 | 100 | 100 | Alpha/beta T-cell lymphopenia with gamma/delta T-cell expansion, severe cytomegalovirus infection, and autoimmunity, 609889 Combined cellular and humoral immune defects with granulomas, 233650 Omenn syndrome, 603554 Severe combined immunodeficiency, B cell-negative, 601457 |
| RAG2 | 221.3 | 100 | 100 | Combined cellular and humoral immune defects with granulomas, 233650 Omenn syndrome, 603554 Severe combined immunodeficiency, B cell-negative, 601457 |
| RASGRP2 | 97.5 | 99 | 98 | ?Bleeding disorder, platelet-type, 18, 615888 |
| RBCK1 | 104.3 | 99 | 94 | Polyglucosan body myopathy 1 with or without immunodeficiency, 615895 |
| RECQL4 | 149.8 | 99 | 96 | Baller-Gerold syndrome, 218600 RAPADILINO syndrome, 266280 Rothmund-Thomson syndrome, 268400 |
| RFX5 | 117.1 | 98 | 96 | Bare lymphocyte syndrome, type II, complementation group C, 209920 Bare lymphocyte syndrome, type II, complementation group E, 209920 |
| RFXANK | 106.1 | 100 | 100 | MHC class II deficiency, complementation group B, 209920 |
| RFXAP | 84.8 | 94 | 91 | Bare lymphocyte syndrome, type II, complementation group D, 209920 |
| RHOH | 135.2 | 100 | 100 | No OMIM phenotype RHOH deficiency (Crequer (2012) J Clin Invest 122,3239) |
| RLTPR | 121.3 | 94 | 92 | |
| RMRP | NC | NC | NC | Anauxetic dysplasia, 607095 Cartilage-hair hypoplasia, 250250 Metaphyseal dysplasia without hypotrichosis, 250460 |
| RNASEH2A | 142.2 | 100 | 99 | Aicardi-Goutieres syndrome 4, 610333 |
| RNASEH2B | 103.8 | 93 | 87 | Aicardi-Goutieres syndrome 2, 610181 |
| RNASEH2C | 209.6 | 100 | 99 | Aicardi-Goutieres syndrome 3, 610329 |

| | | | | |
|----------|-------|-----|----|---|
| RNF168 | 215.5 | 100 | 99 | RIDDLE syndrome, 611943 |
| RNF31 | 154.8 | 99 | 98 | No OMIM phenotype Autoinflammation, immunodeficiency, amylopectinosis and lymphangiectasia (Boisson (2015) J Exp Med 212,939) |
| RPSA | 88.6 | 100 | 99 | Asplenia, isolated congenital, 271400 |
| RSPH9 | 127.6 | 100 | 99 | Ciliary dyskinesia, primary, 12, 612650 |
| RTEL1 | 115.2 | 99 | 95 | Dyskeratosis congenita, autosomal dominant 4, 615190 Dyskeratosis congenita, autosomal recessive 5, 615190 Pulmonary fibrosis and/or bone marrow failure, telomere-related, 3, 616373 |
| SAMHD1 | 127.8 | 99 | 96 | Aicardi-Goutieres syndrome 5, 612952 ?Chilblain lupus 2, 614415 |
| SBDS | 212.4 | 100 | 99 | Shwachman-Diamond syndrome, 260400 {Aplastic anemia, susceptibility to}, 609135 |
| SERAC1 | 112.4 | 98 | 94 | 3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome, 614739 |
| SERPING1 | 98 | 97 | 92 | Angioedema, hereditary, types I and II, 106100 Complement component 4, partial deficiency of, 120790 |
| SH2B3 | 97.5 | 90 | 79 | Erythrocytosis, somatic, 133100 Myelofibrosis, somatic, 254450 Thrombocythemia, somatic, 187950 |
| SH2D1A | 105.3 | 89 | 89 | Lymphoproliferative syndrome, X-linked, 1, 308240 |
| SKIV2L | 24.9 | 16 | 16 | Trichohepatoenteric syndrome 2, 614602 |
| SLC29A3 | 203.8 | 99 | 99 | Histiocytosis-lymphadenopathy plus syndrome, 602782 |
| SLC35A1 | 123.9 | 99 | 97 | Congenital disorder of glycosylation, type IIc, 603585 |
| SLC35C1 | 230.6 | 99 | 98 | Congenital disorder of glycosylation, type IIc, 266265 |
| SLC37A4 | 140.4 | 100 | 99 | Glycogen storage disease Ib, 232220 Glycogen storage disease Ic, 232240 |
| SLC39A4 | 81.9 | 99 | 96 | Acrodermatitis enteropathica, 201100 |
| SLC46A1 | 106.1 | 99 | 96 | Folate malabsorption, hereditary, 229050 |
| SMARCAL1 | 134.9 | 100 | 99 | Schimke immunoosseous dysplasia, 242900 |
| SOCS4 | 262.6 | 99 | 99 | No OMIM phenotype Autoimmunity (Arts (2015) J Intern Med epub,epub) |
| SP110 | 121.7 | 100 | 99 | Hepatic venoocclusive disease with immunodeficiency, 235550 {Mycobacterium tuberculosis, susceptibility to}, 607948 |
| SPINK5 | 145 | 99 | 96 | Atopy, 147050 |

| | | | | |
|--------|-------|-----|-----|--|
| | | | | Netherton syndrome, 256500 |
| STAT1 | 126.2 | 98 | 95 | Immunodeficiency 31A, mycobacteriosis, autosomal dominant, 614892 Immunodeficiency 31B, mycobacterial and viral infections, autosomal recessive, 613796 Immunodeficiency 31C, autosomal dominant, 614162 |
| STAT2 | 116.1 | 100 | 99 | Immunodeficiency 44, 616636 |
| STAT3 | 119.6 | 99 | 99 | Autoimmune disease, multisystem, infantile-onset, 615952 Hyper-IgE recurrent infection syndrome, 147060 |
| STAT4 | 144.1 | 98 | 97 | {Systemic lupus erythematosus, susceptibility to, 11}, 612253 |
| STAT5B | 130.7 | 99 | 97 | Growth hormone insensitivity with immunodeficiency, 245590 Leukemia, acute promyelocytic, somatic, 102578 |
| STAT6 | 119.5 | 100 | 99 | No OMIM phenotype {Schistosomiasis infection, association with} (He (2008) Genes Immun 9, 195) {Atopic asthma, association with} (Gao (2004) J Med Genet 41,535) |
| STIM1 | 127.2 | 100 | 99 | Immunodeficiency 10, 612783 Myopathy, tubular aggregate, 1 160565 Stormorken syndrome, 185070 |
| STK4 | 139 | 100 | 99 | T-cell immunodeficiency, recurrent infections, autoimmunity, and cardiac malformations, 614868 |
| STX11 | 312.1 | 100 | 100 | Hemophagocytic lymphohistiocytosis, familial, 4, 603552 |
| STXBP2 | 125.3 | 98 | 97 | Hemophagocytic lymphohistiocytosis, familial, 5, 613101 |
| TAP1 | 12.9 | 12 | 12 | Bare lymphocyte syndrome, type I, 604571 |
| TAP2 | 15.2 | 15 | 15 | Bare lymphocyte syndrome, type I, due to TAP2 deficiency, 604571 Wegener-like granulomatosis |
| TAPBP | 20.2 | 19 | 18 | Bare lymphocyte syndrome, type I, 604571 |
| TAZ | 94.9 | 99 | 98 | Barth syndrome, 302060 |
| TBX1 | 75.5 | 77 | 67 | Conotruncal anomaly face syndrome, 217095 DiGeorge syndrome, 188400 Tetralogy of Fallot, 187500 Velocardiofacial syndrome, 192430 |
| TCIRG1 | 113.7 | 95 | 89 | Osteopetrosis, autosomal recessive 1, 259700 |
| TCN2 | 175.9 | 100 | 100 | Transcobalamin II deficiency, 275350 |
| TERC | NC | NC | NC | Dyskeratosis congenita, autosomal dominant 1, 127550 {Aplastic anemia}, 614743 {Pulmonary fibrosis, idiopathic, susceptibility to}, 614743 |

| | | | | |
|-----------|-------|-----|-----|--|
| TERT | 138.6 | 95 | 92 | {Dyskeratosis congenita, autosomal dominant 2}, 613989 {Dyskeratosis congenita, autosomal recessive 4}, 613989 {Leukemia, acute myeloid}, 601626 {Melanoma, cutaneous malignant, 9}, 615134 {Pulmonary fibrosis and/or bone marrow failure, telomere-related, 1}, 614742 |
| TFRC | 157.3 | 99 | 99 | Immunodeficiency 46, 616740 |
| THBD | 108.4 | 99 | 97 | Thrombophilia due to thrombomodulin defect, 614486 {Hemolytic uremic syndrome, atypical, susceptibility to, 6}, 612926 |
| TICAM1 | 111.5 | 100 | 99 | {Herpes simplex encephalitic, susceptibility to, 6}, 614850 |
| TINF2 | 183.9 | 100 | 100 | Dyskeratosis congenita, autosomal dominant 3, 613990 Revesz syndrome, 268130 |
| TIRAP | 136.5 | 100 | 100 | {Bacteremia, protection against}, 614382 {Malaria, protection against}, 611162 {Pneumococcal disease, invasive, protection against}, 610799 {Tuberculosis, protection against}, 607948 |
| TLR3 | 185.7 | 99 | 98 | {Herpes simplex encephalitis, susceptibility to, 2} 613002 {HIV1 infection, resistance to}, 609423 |
| TLR4 | 132.2 | 100 | 99 | Endotoxin hyporesponsiveness {Colorectal cancer, susceptibility to}, 114500 {Macular degeneration, age-related, 10}, 611488 |
| TMC6 | 83.8 | 99 | 99 | Epidermodysplasia verruciformis, 226400 |
| TMC8 | 108.1 | 97 | 91 | Epidermodysplasia verruciformis, 226400 |
| TMEM173 | 100.8 | 98 | 93 | STING-associated vasculopathy, infantile-onset, 615934 |
| TNFAIP3 | 136.1 | 100 | 99 | Autoinflammatory syndrome, familial, Behcet-like, 616744 |
| TNFRSF11A | 147 | 93 | 91 | Osteolysis, familial expansile, 174810 Osteopetrosis, autosomal recessive 7, 612301 {Paget disease of bone 2, early-onset}, 602080 |
| TNFRSF13B | 111.2 | 100 | 99 | Immunodeficiency, common variable, 2, 240500 Immunoglobulin A deficiency 2, 609529 |
| TNFRSF13C | 55.9 | 76 | 66 | Immunodeficiency, common variable, 4, 613494 |
| TNFRSF1A | 93.2 | 90 | 87 | Periodic fever, familial, 142680 {Multiple sclerosis, susceptibility to, 5}, 614810 |
| TNFRSF4 | 51.7 | 97 | 85 | ?Immunodeficiency 16, 615593 |
| TPP2 | 119.2 | 98 | 94 | No OMIM phenotype |

| | | | | |
|----------|-------|-----|-----|---|
| | | | | Evans syndrome, immunodeficiency and premature immunosenescence (Stepensky (2015) Blood 125, 753) |
| TRAF3 | 130.8 | 99 | 98 | {?Herpes simplex encephalitis, susceptibility to, 3}, 614849 |
| TRAF3IP2 | 116.8 | 99 | 97 | ?Candidiasis, familial, 8, 615527 {Psoriasis susceptibility 13}, 614070 |
| TREX1 | 242.7 | 100 | 100 | Aicardi-Goutieres syndrome 1, dominant and recessive, 225750 Chilblain lupus, 610448 Vasculopathy, retinal, with cerebral leukodystrophy, 192315 {Systemic lupus erythematosus, susceptibility to}, 152700 |
| TRNT1 | 104.6 | 97 | 92 | Retinitis pigmentosa and erythrocytic microcytosis, 616959 Sideroblastic anemia with B-cell immunodeficiency, periodic fevers, and developmental delay, 616084 |
| TTC37 | 123.9 | 99 | 98 | Trichohepatoenteric syndrome 1, 222470 |
| TTC7A | 121.4 | 99 | 98 | Gastrointestinal defects and immunodeficiency syndrome, 243150 |
| TYK2 | 119.5 | 99 | 98 | Immunodeficiency 35, 611521 |
| UNC119 | 93.1 | 97 | 90 | ?Cone-rod dystrophy ?Immunodeficiency 13, 615518 |
| UNC13D | 97.1 | 99 | 97 | Hemophagocytic lymphohistiocytosis, familial, 3, 608898 |
| UNC93B1 | 60.1 | 56 | 54 | {Herpes simplex encephalitis, susceptibility to, 1}, 610551 |
| UNG | 78.6 | 99 | 94 | Immunodeficiency with hyper IgM, type 5, 608106 |
| USB1 | 125 | 99 | 98 | Poikiloderma with neutropenia, 604173 |
| VPS13B | 143.7 | 98 | 96 | Cohen syndrome, 216550 |
| VPS45 | 130.7 | 96 | 94 | Neutropenia, severe congenital, 5, autosomal recessive, 615285 |
| WAS | 66.6 | 88 | 78 | Neutropenia, severe congenital, X-linked, 300299 Thrombocytopenia, X-linked, 313900 Thrombocytopenia, X-linked, intermittent, 313900 Wiskott-Aldrich syndrome, 301000 |
| WIPF1 | 77.5 | 100 | 99 | ?Wiskott-Aldrich syndrome 2, 614493 |
| WRAP53 | 154.5 | 100 | 100 | Dyskeratosis congenita, autosomal recessive 3, 613988 |
| XIAP | 107.8 | 91 | 86 | Lymphoproliferative syndrome, X-linked, 2, 300635 |
| ZAP70 | 186.2 | 99 | 99 | Autoimmune disease,multisystem,infantile-onset,2,617006 Immunodeficiency 48,269840 |
| ZBTB24 | 177.8 | 100 | 100 | Immunodeficiency-centromeric instability-facial anomalies syndrome-2, 614069 |

Gene symbols used follow HGNC guidelines: Gray KA, Yates B, Seal RL, Wright MW, Bruford EA. Nucleic Acids Res. 2015 Jan;43(Database issue):D1079-85.
 Median Coverage describes the average number of reads seen across 50 exomes.

% Covered 10x describes the percentage of a gene's coding sequence that is covered at least 10x.

% Covered 20x describes the percentage of a gene's coding sequence that is covered at least 20x.

Genes with Median Coverage and % Covered 10x/20x denoting NC are non-coding genes for which coverage statistics could not be generated.

OMIM release used for OMIM disease identifiers and descriptions : April 14th, 2017.

This list is accurate for panel version DG 2.11

Ad 1. "No OMIM phenotype" signifies a gene without a current OMIM association Ad 2. OMIM phenotype descriptions between {} signify risk factors
